FDA approves baricitinib for severe alopecia areata in adolescents 12+, with 42% achieving 80% scalp hair coverage in Phase...

Evorpacept's Phase 2 data in HER2+ gastric cancer reveals a CD47 biomarker selection gap that could reshape how oncology...

Phase III trial amendments now average 3.5 per study, up from 2.3 a decade ago, with each costing a...

Tekton Research hires three VPs to strengthen multi-site trial growth, addressing sponsor demands for better coordination and participant retention...

XtalPi's KQTD-126, a gut-restricted TRK inhibitor, targets chronic intestinal pain in IBS and IBD with a tissue-to-blood ratio above...

Acadia reports Phase 2 results for remlifanserin in Alzheimer's disease psychosis, with Phase 3 trials already underway and FDA...

Kyverna reports one-year miv-cel data in stiff person syndrome showing durable clinical responses and favorable safety, supporting potential registrational...

Sefaxersen meets primary endpoint in Phase 3 IgA Nephropathy trial, showing statistically significant proteinuria reduction in adults with primary...

Teclistamab plus daratumumab demonstrated an 18-percentage-point survival advantage at 3 years in relapsed multiple myeloma patients with 1–3 prior...

aTyr Pharma reaches FDA protocol agreement for efzofitimod Phase 3 trial in pulmonary sarcoidosis, paving the way for global...